The transaction, which is entirely consistent with the Bomi Group's strategy of external growth and expansion, involves the payment of a maximum consideration, for the three businesses, of about Euro 1.3 million, comprising a fixed component, payable on completion of the acquisition, of about Euro 120,000, and several variable earn-out components for the remainder (totalling about Euro 1.2 million) tied respectively (i) to the agreement of some clients to the transaction (ii) to securing contracts with core clients, or (iii) on achieving a pre-determined level of revenues. The earn-out components will be paid over a 12 - 24 month time period following completion of the acquisitions depending on the achievement of the expected results.
On completion of the transaction, Biomedical Distribution France SAS will change its corporate legal name to "Distrimedical SAS", while continuing to operate under the "Bomi" brand.
This transaction will allow Bomi Group to consolidate its expected revenues in the French market as well as to reinforce its own position in the region through investment in companies with recognised expertise in the field of biomedical logistics and which are also leaders in their markets. This acquisition, in addition to growing its presence in the French market also achieves the objective - which is perfectly in line with the Group's growth and development strategy - of acquiring "core" clients to provide them with high value-added services in target markets and at a global level in other countries where the Group is already present.
Giorgio Ruini - Chairman of Bomi Italia S.p.A. - and Jovic Radè - Chairman of Distritec SAS - commenting on the transaction, stated: "This operation represents a significant step in the growth of Bomi Group in Europe. This partnership with DGroup, the leading French company in technical transport for the healthcare sector, that can record a constant growth of more than 10 % of turnover during the last 5 years, allows us to consolidate the services offered in the transport sector and in the management of biomedical sector products and to offer to the new clients acquired, additional value added services typical of Bomi Group."
Bomi Group's activities are concentrated in the integrated logistics sector and offer a wide range of logistics services in outsourcing to companies operating in the healthcare sector, managing distribution of medical equipment, pharmaceuticals, in- vitro diagnostic equipment, reagents and implant products.
Bomi Group's portfolio of about 100 clients includes some of the world's top healthcare companies (such as the leading pharmaceutical companies and producers of healthcare devices) as well as small and medium sized companies operating at a global level in the biomedical, diagnostics and biotech industries. Bomi Group currently has about 850 employees and operates through subsidiary companies and significant investments in Europe, South America and the United States and its services are also provided, through strategic alliances with local partners, in several other countries including Mexico and China.
ISIN Ordinary Share Code: IT0005108784 - Ordinary Share Ticker: BOMI
ISIN Convertible Bond Code: IT00051114480 - Convertible Bond Ticker: BOMI20
For further information
|
Investor Relations tel: +39 03962781313 |
e.mail: investorrelator@bomigroup.com |
|
Nominated Adviser tel: +390514850990 |
e.mail: stefano.taioli@popvi.it |
Bomi Italia S.p.A. issued this content on 21 March 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 22 March 2016 08:28:13 UTC
Original Document: http://bomigroup.com/files/investor-relations/Comunicati Stampa/Marzo 2016/BOMI - Communicato stampa ENG 180316.pdf